Characterizing the pathogenicity of DNA sequence variants of unknown significance (VUS) is a major bottleneck in human genetics, and is increasingly important in determining which patients with inherited retinal diseases could benefit from gene therapy. A library of 210 rhodopsin (RHO) variants from literature and in-house genetic diagnostic testing were created to efficiently detect pathogenic RHO variants that fail to express on the cell surface. This study, while focused on RHO, demonstrates a streamlined, generalizable method for detecting pathogenic VUS. A relatively simple next-generation sequencing-based readout was developed so that a flow cytometry-based assay could be performed simultaneously on all variants in a pooled format, without the need for barcodes or viral transduction. The resulting dataset characterized the surface expression of every RHO library variant with a high degree of reproducibility (r 2 = 0.92-0.95), recategorizing 37 variants. For example, three retinitis pigmentosa pedigrees were solved by identifying VUS which showed low expression levels (p.G18D, p.G101V, and p.P180T). Results were validated across multiple assays and correlated with clinical disease severity. This study presents a parallelized, higher-throughput cell-based assay for the functional characterization of VUS in RHO, and can be applied more broadly to other inherited retinal disease genes and other disorders. K E Y W O R D S functional genomics, inherited retinal diseases, next-generation sequencing, retinitis pigmentosa, rhodopsin, variant library, variant pathogenicity, variant of unknown significance, VUS
systems can attempt to manage uncertainty in pathogenicity, but clearly, it would be preferable to have more information about a variant to decrease the uncertainty level.
Current bioinformatic approaches to predicting variant pathogenicity are impressive in that they efficiently produce large numbers of predictions about very complex biological systems, but they are not sufficient to meet the increasing expectations about the fidelity of these predictions (Richards et al., 2015) . For example, older algorithms for predicting the pathogenicity of missense mutations, many still in use, are only 65-80% accurate (Thusberg, Olatubosun, & Vihinen, 2011) , and specificity for the predictions of pathogenicity of missense and splice variants can be low (Choi, Sims, Murphy, Miller, & Chan, 2012; Houdayer et al., 2012; Kircher et al., 2014) . The latest techniques are raising the quality of the predictions, for example with ROC curve areas of 0.72-0.86 (Caminsky, Mucaki, & Rogan, 2014; Gray, Hause, Luebeck, Shendure, & Fowler, 2018) , but in the end, the state-of-the-art is that "it is not recommended that these (bioinformatic) predictions be used as a sole source of evidence to make a clinical assertion" about a potentially pathogenic variant (Richards et al., 2015) . In fact, "well-established functional studies showing a deleterious effect" is considered two levels-of-evidence higher than "multiple lines of computational evidence support(ing) a deleterious effect on the gene/gene product" (italics added; Richards et al., 2015) .
Again, while the bioinformatic predictions are becoming even more impressive, and expected to become even more accurate when trained with more empirical data (Gray et al., 2018) , empirical wetlab functional assays are still required to achieve the level of accuracy desired to, for example, decide whether a patient is eligible for gene therapy treatment (Cideciyan et al., 2018) .
VUS not only cloud the interpretation and utility of clinical diagnostic testing, but also can lead to outliers and ambiguities when analyzing structure-function relationships of proteins of interest (Rakoczy, Kiel, McKeone, Stricher, & Serrano, 2011) . For example, when correlating the computational prediction of misfolding propensity and the age of onset of disease among rhodopsin (RHO) mutants, some mutations are considered outliers and excluded from the regression analyses (Rakoczy et al., 2011) ; however, it is not clear whether the outliers could be due to imperfect computational models or to miscategorization of the mutant. Thus, improving the characterization of DNA variants is scientific importance, and has been included U.S. federal research priorities and identified as a knowledge gap in the understanding of inherited retinal diseases (Duncan et al., 2018; National Eye Institute, 2012) .
This study implements an improved method to characterize potentially pathogenic DNA variants causing retinitis pigmentosa (RP).
RP accounts for up to 25% of blindness or visual impairment in workingage people (21-60 years; Al-Merjan, Pandova, Al-Ghanim, Al-Wayel, & Al-Mutairi, 2005; Buch et al., 2004; Hartong, Berson, & Dryja, 2006; Hata, Yonezawa, Nakanishi, Ri, & Yanashima, 2003) , and therefore it is an important cause of vision loss. Although RP is a Mendelian disease, it is genetically very heterogeneous, with mutations in over 60 different genes that can cause nonsyndromic RP (Berger, Kloeckener-Gruissem, & Neidhardt, 2010; Daiger, Rossiter, Greenberg, Christoffels, & Hide, 1998; RetNet, 2017) . Genetic testing to identify the cause of disease has become increasingly important as more clinical trials for RP focus on patient populations with specific genotypes, for example, studies recruiting MERTK-, MYO7A-, PDE6A-, PDE6B-, RPGR-, or RLBP1-affected RP patients (U.S. National Institutes of Health, 2017), as well as the occasional RP patient due to RPE65 mutations who would be eligible for the first food and drug administration (FDA)-approved gene therapy, voretigene neparvovec (Luxturna; Russell et al., 2017) . Patients without a genetic diagnosis are not eligible for gene-specific treatments. Despite the practical importance of obtaining a genetic diagnosis, definitive causal variant(s) can be found in only about half of patients, and slightly more using the latest next-generation sequencing (NGS) techniques Corton et al., 2013; Glockle et al., 2014; Huang, Wu, Lv, Zhang, & Jin, 2015; Neveling et al., 2012; Wang et al., 2014) . For this reason, improving the characterization of DNA variants in RP is also of practical importance.
This study focuses on RHO mutants because RHO has the largest set of known pathogenic variants of any dominant RP gene, and among those genes, the structural, biochemical, and cell biological understanding of RHO is unmatched (Athanasiou et al., 2018; Behnen et al., 2018; Dryja, Berson, Rao, & Oprian, 1993; Krebs et al., 2010; McKeone, Wikstrom, Kiel, & Rakoczy, 2014; Mendes & Cheetham, 2008; Mendes, van der Spuy, Chapple, & Cheetham, 2005; Mendes, Zaccarini, & Cheetham, 2010; Rakoczy et al., 2011) . The rich body of existing data provides a context for interpreting data on new variants, and conversely, provides an opportunity to refine existing models of RHO structure and function (Rakoczy et al., 2011) . A recent review (Athanasiou et al., 2018) notes that ongoing questions about the pathogenicity of RHO variants "reinforce the need for thorough genetics, such as segregation analyses, and in-depth functional analyses to confirm pathogenicity." (Note that the term "variant" is used in this study to include any sequence change, whether that sequence change is a "mutant" i.e., known to be pathogenic, a VUS, or a benign change such as a synonymous control.)
Standard experimental methods of assaying RHO variants include assessment of surface expression/subcellular localization in cellbased assays (Behnen et al., 2018; Chen, Wang, Lin, & Chen, 2011; Chuang, Vega, Jun, & Sung, 2004; Davies et al., 2012; Hollingsworth & Gross, 2013; Li et al., 1998; Liu et al., 2013; McKeone et al., 2014; Sung, Davenport, & Nathans, 1993; Toledo et al., 2011; Yamasaki et al., 2014) and assessment of bulk biochemical properties (Bosch, Ramon, Del Valle, & Garriga, 2003; Bosch-Presegue, Ramon, Toledo, Cordomi, & Garriga, 2011; Dizhoor et al., 2008; Krebs et al., 2010; Opefi, South, Reynolds, Smith, & Reeves, 2013) . These assays are performed on one variant at a time, and, especially for the biochemical assays, do not scale easily for larger numbers of variants.
The purpose of this study was to develop higher-throughput cellbiological methods to evaluate RHO variants for pathogenicity for example, a "functional genomics" approach. We hypothesized that this approach would result in the improved categorization of RHO DNA variants compared with using computational information alone.
We also hypothesized that pedigrees with inconclusive genetic testing results and an RHO VUS could be solved using the functional data. This study presents a streamlined functional genomic screen ( Figure 1 ) suitable for assaying hundreds of variants, using standard mutagenesis, transfection, flow cytometry, and NGS amplicon sequencing techniques that are broadly available. The bioinformatic analysis was custom-built, but also straightforward. (Chen et al., 2011; Chuang et al., 2004; Davies et al., 2012; Hollingsworth & Gross, 2013; Li et al., 1998; Liu et al., 2013; McKeone et al., 2014; Sung et al., 1993; Toledo et al., 2011; Yamasaki et al., 2014) . Also, it is a robust transfection host, and for the multiplexed assays a high transfection rate was useful to preserve library diversity. The transfection was performed in an unpooled format (one variant per well), because preliminary experiments showed that a pooled transfection at limiting dilutions of DNA, such that each cell expresses a single variant, did not produce sufficient expression (not shown). The selected pathogenicity assay was a quantification of cell surface expression of RHO using antibody staining with indirect immunofluorescence, as reported (for example, McKeone et al., 2014;  any mutant protein that misfolds and fails to be detected on the cell surface was identified as pathogenic, whether that mutation is dominantly or recessively inherited in humans). We then used two different methods to implement this pathogenicity assay on the transfected cells-first, we used an unpooled format using flow cytometry analysis of RHO surface expression, which is similar to published methods (e.g. McKeone et al., 2014) and served as a validation of the system. Then, we used a method where the transfected cells from every variant were pooled (Figure 1 ), allowing for higher throughput, parallelized assay. Fluorescence-activated cell sorting (FACS) was used because it allowed for a large number of cells (~10 6 ) to be assayed and sorted into pools for NGS analysis in parallel.
Amplicon sequencing of the entire RHO complementary DNA (cDNA) plasmid, rather than an implementation of plasmid barcodes for each variant, was a simpler approach given the number of variants under study (~10 2 , see Section 4).
More intricate functional genomic screens have been recently developed that interrogate thousands of variants at once (Melnikov, Rogov, Wang, Gnirke, & Mikkelsen, 2014; Brenan et al., 2016; Findlay et al., 2018; Gasperini, Starita, & Shendure, 2016) but these methods require specialized library construction techniques, lentivirus packaging, and viral transduction followed by selection, which were not needed for this study of 210 variants.
Overall, a functional genomics approach was used to create a library of RHO variants and precisely assay their surface expression in an efficient format.
| MATERIALS AND METHODS

| Identification of RHO variants
A literature review (PubMed) and database search (HGMD, ClinVar) identified 211 known RHO variants. Twenty-two database variants were not created due to technical complexity (large insertions, large deletions, in an intron, or in an untranslated region), due to likely incompatibility with pathogenicity (a high-allele-frequency synonymous allele), or due to never having been reported in humans ("synthetic") . See Table S1 . The remaining 189 variants were added to the variant library and of those, 175 were known as pathogenic, causing dominant RP, recessive RP, or congenital stationary night F I G U R E 1 Experimental design of library screening for VUS characterization. An expression plasmid library of RHO variants was constructed using mutagenesis. (Four variants are shown as an example.) Each variant plasmid was individually transfected into a well of cells, and the cells were then pooled after transfection. The cells, after expressing the desired variant, were stained using a fluorescent pathogenicity assay based on RHO surface expression (fluorescent antibody). Fluorescence-activated cell sorting was used to separate high-and low-expressing cells. Each transfected cell carries with it the DNA of the variant of interest, and this "tag" can be sequenced using NGS and therefore count the relative frequency of each DNA variant in each pool, quantifying the pathogenicity of each variant in parallel. NGS: next-generation sequencing; RHO: rhodopsin; VUS: variants of unknown significance WAN ET AL.
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blindness. (Table S1 ) 14 variants were of uncertain significance or thought to be benign polymorphisms. All of the variants were well distributed across the cDNA, except that there were no variants between bp 664 and 745, which corresponds to cytoplasmic loop 3 of RHO (Zhou, Melcher, & Xu, 2012 ; DNA descriptors in this study refer to NM_000539.3 and protein descriptors refer to NP_000530.1 also known as RHO_v001).
A group of 11 individual synonymous mutations, expected to have a similar expression to wildtype and to serve as controls, was designed synthetically (Table S1 ). The mutations were placed near the 3′-end of the gene to minimize any possible (though unexpected) changes to transcriptional or translational processes (Stoletzki & Eyre-Walker, 2007) . In addition, a search for rare (detected <3 times in our internal database, ExAC allele frequency <10 −4 ) RHO VUS from patient DNA sequencing performed in our institutionʼs genetic testing service , identified 10 variants spanning 11 probands. All of these variants were novel (previously unreported in patients) at the beginning of this study. Altogether, 232 RHO variants were identified and 210 were ultimately constructed as a variant library: 189 variants from literature/ databases, 11 synonymous controls, and 10 novel VUS.
The study protocol adhered to the tenets of the Declaration of Helsinki and was approved by the Institutional Review Board of Massachusetts Eye and Ear. 
| RHO variant cDNA library construction
| Cell culture
HEK293 cells (American Type Culture Collection) were cultured using aseptic technique and grown in 10% fetal bovine serum (FBS) in Dulbeccoʼs modified Eagleʼs medium serum without antibiotics. Cells were grown at 37°C and 5% CO 2 in a standard cell culture incubator and passaged at subconfluent densities every 2-3 days as needed.
| RHO transfection and surface expression assays by immunofluorescence
All transfections were performed using Lipofectamine 2000 (11668019; Thermo Fisher Scientific) on HEK293 cells seeded at a density of 200 cells/mm 2 on tissue culture dishes. The day after seeding, the media was refreshed and the transfection mixture added as described below. Samples were collected 48 hr after transfection.
| Immunofluorescence microscopy
Glass coverslips were placed in wells before cell seeding into six-well dishes. Transfection was performed using 2 μg plasmid DNA and 3 μl Lipofectamine in 150 μl Opti-MEM I (31985062; Thermo Fisher Scientific). At collection, cells on coverslips were fixed in 4% paraformaldehyde for 20 min and blocked with 3% bovine serum albumin in phosphate-buffered saline for 10 min before applying Ret-P1 anti-RHO antibody (#O4886; Millipore, Sigma, Burlington, MA) at a final concentration of 1:1,000 in blocking buffer for 1 hr. After washing with PBS, Alexafluor-488 goat anti-mouse antibody (A-11029; Thermo Fisher Scientific) was applied at a final concentration of 1:300 in blocking buffer for 1 hr and Hoechst 33342 (#H3570; Thermo Fisher Scientific) applied for 1-5 min at a concentration of 1:5,000. Coverslips were mounted onto slides with Fluoromount G and dried overnight at room temperature. Slides were kept at 4°C before viewing on a Nikon TI Eclipse microscope or Leica TCS SP5 confocal microscope.
| Flow cytometry
Transfection was performed in 24-well plates using 0.5 μg plasmid and 1.5 μl Lipofectamine in 50 μl Opti-MEM I. At collection, the cells were washed briefly with PBS and then 200 μl trypsin added and allowed to incubate for 4 min at 37°C. A 300 μl aliquot full media was then added, and cells collected into 2.2-ml tubes. The cells were centrifuged at 400g in a floor centrifuge for 4 min and the supernatant aspirated. Cells were fixed in 4% PFA for 20 min and blocked with 3% BSA in PBS before applying the Ret-P1 primary antibody at a final concentration of 1:1,000 in blocking buffer for 30 min. After washing with PBS, Alexfluor-488 secondary antibody was applied at a final concentration of 1:300 in blocking buffer for 30 min. After a final PBS wash, cells were analyzed on a BD LSRII Flow Cytometer. 
| FACS
Cells were prepared as described for flow cytometry analysis but pooled after transfection and then fixed in zinc-based fixative (ZBF; #550523; BD Pharmingen) instead of 4% PFA (ZBF was used because PFA fixation/crosslinking prevented downstream PCR amplification of residual plasmid DNA [Wester et al., 2003] , while unfixed cells did not stain with Ret-P1 antibody). All subsequent washes substituted Tris-buffered saline (TBS) for PBS to reduce salt precipitation. Cells were sorted into TBS or PBS with 1% FBS using a BD SORP 5 Laser Vantage SE DIVA. Replicate samples were derived from independent transfections on different weeks (n = 3).
Additional experiments to implement a pooled transfection method were not effective; at standard plasmid concentrations, large numbers of different variants entered each cell causing every cell to stain similarly, while at low plasmid concentrations, not enough RHO expression was achieved for robust staining and cell sorting (not shown).
| RHO cDNA OR RNA extraction and amplification from sorted cells
Immediately after sorting, cells (from 4 × 10 4 to 2.3 × 10 6 ) were pelleted at 400g for 4 min and resuspended in 700 μl RLT buffer (Qiagen) with β-mercaptoethanol (1:100), mixed and aliquoted into two samples of 350 μl each and stored at −80°C until extraction.
Plasmid DNA and total RNA were isolated. Preliminary experiments (not shown) demonstrated that RNEasy mini columns (#74104; Qiagen) can isolate both RNA and the relatively low molecular weight plasmid DNA in one step using the manufacturerʼs standard RNA isolation protocol. However, as on-column DNAse treatment performed more reliably for the RNA preparation, the cells were separated into two aliquots loaded on separate columns: For total RNA extraction, the manufacturerʼs standard RNEasy protocol was followed, including on-column DNAse digestion (#79254; Qiagen). was used to create cDNA and then the cDNA was amplified by PCR.
The following program was used: (a) 50°C for 30 min; (b) 95°C for 15 min; (c) 36 cycles 94°C for 30 s, 50°C for 30 s, 72°C for 1 min; (d) 72°C for 10 min. One microliter of each 100 μl reaction was run on a Tapestation (Agilent) to determine approximate size and concentration and to confirm the presence of a single band of an amplified template. Negative control reactions (minus RT for RNA, plus DNAse for DNA) showed no cross-amplification between samples that were intended to amplify RNA or DNA, respectively. PCR reactions were processed through a PCR clean-up column (#28104; Qiagen, Germantown, MD), and the concentration determined using a QuBit dsDNA HS Assay (Q32854; Thermo Fisher Scientific). 
| NGS amplicon sequencing without library barcodes
| Bioinformatic quantitation of low-frequency variants in NGS amplicon sequencing
Most variant callers are designed to work with diploid genomes and do not call variants present at less than about 50% frequency.
Extensive testing with specialized low-frequency variant callers (Spencer et al., 2014) showed that these variant callers, including "lofreq" (Wilm et al., 2012) , did not accurately call all variants, particularly small insertions/deletions (a known limitation of alignment algorithms; Jiang, Turinsky, & Brudno, 2015) . Additional analyses with MuTect (Cibulskis et al., 2013) or MuTect2 showed low sensitivity using default settings, and settings with appropriate sensitivity and specificity were not identified (not shown). WAN ET AL.
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Multinucleotide polymorphisms (e.g. 511_512delCCinsGA) were particularly problematic.
Therefore, an alignment-free approach was used to detect and quantify low-frequency variants in NGS data when the variants are known. This algorithm uses no alignment step and simply counts the number of exact-match occurrences of a 20 bp "probe" sequence string designed for each known variant. The "probes" (in analogy to Southern blot probes), were designed in silico containing each of the known 210 nucleotide changes. In most cases, the primer used for QuikChange mutagenesis was simply trimmed to 20 bp to create the "mutant probe".
A corresponding "wildtype probe" was created to quantify and normalize for variations in coverage. To estimate signal-to-noise ratio in the context of NGS sequencing errors (Fox, Reid-Bayliss, Emond, & Loeb, 2014) , a "noise probe" was manually created containing an alternate nucleotide change which was not present in the wildtype or mutant probes. Each occurrence of these 630 probes (wildtype, mutant, or noise × 210 variants) was counted in the text of each sampleʼs FASTQ file using the Linux tool grep, similar to a strategy previously published (Bujakowska, White, Place, Consugar, & Comander, 2015) .
The coverage at both ends of the amplicon was overrepresented, presumably due to the sequencing of the residual unsheared amplicon.
Preliminary experiments showed that the signal-to-noise ratio was low for some variants, particularly at amplicon ends, where early MiSeq cycles had a lower base call quality value. Thus, before quantifying the frequency of each probe in each FASTQ file, a script was implemented to censor all FASTQ files on a base pair-by-base pair basis for a high-quality Q score from 36 to 41 ("E" to "J"), resulting in improved signal-to-noise ratio (not shown). For graphing, signal-to-noise ratios were capped at 1,000 when zero noise probes were detected. Run-time for quantification of the entire dataset was about 2 hr on our local computer cluster. These scripts are available at https://github.com/jcomand/VariantCounting. The experimental design called for relative quantitation of each variant in two pools of transfected and sorted cells, in this case, "high" versus "low" surface-RHO-expressing cells. The raw read counts of each mutant probe were normalized to the read depth of the wildtype probe. that is the final "NGS ratio" used for analysis was the number of read counts: mutant probe_high/wildtype probe_high/ mutant probe_low/wildtype probe_low. Three independent biological experiments (e.g. separate transfections on different weeks) were converted to log-ratios for calculation of averages and standard errors for each variant. This log transformation was sufficient to produce approximately normally distributed ratios in this dataset with relatively large read counts (not shown); however for a dataset with small read counts, a transformation of the counts would be required (Viner, Dorman, Shirley, & Rogan, 2014 ).
| Predicting clinical disease severity
Clinical outcomes of subjects with RHO mutations have previously been published, including by our institution (Berson, Rosner, Weigel-DiFranco, Dryja, & Sandberg, 2002) . Electroretinography (ERG) data were analyzed from these subjects and subsequent subjects with RHO mutations from later years. The baseline (first visit) 30 Hz cone flicker ERG amplitude was used as the clinical outcome measure, as it has a broad dynamic range (>3 log units) across disease severities (Berson et al., 2002) . Other ERG parameters or other outcomes such as visual field area and visual acuity were not used, to avoid multiple testing. To maximize sample size, data from DNA variants with the same amino acid change were pooled. Of the amino acid changes represented in the clinical data, class 2 (misfolding) mutations were the only biochemical category (Rakoczy et al., 2011) that had more than two mutations represented. The analysis was therefore limited to subjects with class 2 mutations (n = 69 subjects; class 2 mutations also have the best biological rationale and precedent for correlating with disease severity in this assay; Athanasiou et al., 2018; Rakoczy et al., 2011) Figure 2 shows an example of a clinical situation in which an inconclusive genetic testing result, including a rare RHO VUS, was obtained for a proband with RP. Of the 210 RHO variants identified for this study, 10 variants were from rare RHO VUS that were discovered in DNA samples from subjects with inherited retinal diseases (See Section 2 and Table   S1 ). Figure 2a shows the fundus appearance of one of these 10 subjects (D00726) who was diagnosed with RP after a full clinical evaluation. In this Mendelian disorder, it is most likely that variant (s) in a single gene are truly pathogenic. Figure 2b shows the large number of VUS identified in genetic testing for this subject using panel-based sequencing of inherited retinal disease genes (GEDi test; Consugar et al., 2015) . The RHO p.P180T variant (row 3) is predicted to be pathogenic, but so are other VUS to varying degrees, two of which are coding variants in genes that can cause dominantly-inherited RP (SNRNP200 and RP1). An expert in ocular genetics may suspect that the RHO variant is the most likely to be pathogenic, but it is not conclusive. Therefore, additional functional data are needed.
| Flow cytometry assay validation
RHO variant plasmids (n = 210) were created using site-directed mutagenesis and these were then cloned into an expression vector suitable for transfection into cultured cells. The next step (Figure 1) was to optimize a fluorescent assay to identify which variants have pathogenic surface expression levels. Based on the assay by McKeone et al. (2014) , Figure 3 shows that indirect immunofluorescence staining successfully distinguishes between wildtype RHO and known mutant (p.P23H) RHO. In this case, whereas the wildtype RHO was expressed well on the cell surface, the p.P23H mutant did not express on the cell surface but rather was trapped inside the cell as expected. The results were validated using nonpermeabilized cells to ensure that only surface RHO was detected (Figures 3a,b) ; flow cytometry results corresponded to the immunofluorescence staining patterns (Figure 3c ). By comparing flow cytometry results from wildtype and p.P23H mutant RHO as positive and negative controls, respectively, the assay to separate wildtype from p.P23H mutant RHO was highly reproducible (Z' = 0.94; Figure 3d ; Z' is a measure of statistical effect size, used in high-throughput screening to judge whether the response in a particular assay is large enough to warrant further attention). While this performance in distinguishing p.P23H versus wildtype RHO does not guarantee that all mutants will be detected with the same level of fidelity, it suggests that this assay is appropriate for use in a "high-throughput screening" context.
Each of the 210 variants in the library was then tested by flow cytometry using two methods for comparison: (a) the standard unpooled flow cytometry assay in which each variant is maintained in a separate tube and analyzed separately (Figure S1); and (b) a pooled assay in which transfected cells are then pooled and FACS is used to sort RHO high-expressing versus low-expressing cells (Figure 4a ).
The entire cDNA within the transfected plasmid (inside the cell) serves as the "barcode" and allows deconvolution/quantitation of the level of each variant that is represented in the high and low pools.
The residual plasmid is isolated from each cell pool, amplified by PCR and sequenced by NGS.
| Validation of string-based pooled variant detection and quantification
All 210 library variants were detected at a coverage-normalized frequency that was >1.5 of that observed by sequencing a wildtype RHO amplicon with no variants (Figure 4b) . Two hundred and seven of the 209 variants were seen at >×2. One variant which was used in the positive control sample during flow cytometry (diamond) showed overrepresentation, possibly due to cross-contamination at the flow cytometry stage; this was minimized in future iterations.
Next, intra-sample quality control was performed by evaluating the level of the "noise probes" as described in the Methods. Customized computational filtering of sequencing quality scores was needed to obtain high signal-to-noise data. Figure 4c shows the signal-to-noise (S-N) ratio as a function of location in the cDNA. All variants were detected with a S-N ratio >1.5×, and with 208 of 210 detected at >2× (Figure 4c ).
The starred cluster of points (Figure 4c ) with a lower, but acceptable, S-N ratio is from variants located near a sequencing error-prone sequence context that is GC rich with a poly-C repeat (GGCCCCGGCC). There are a large number of reported variants in this region (Table S1) , and in the 3′-end of the coding region in Figure 6 ). Of note, while the box-and-whiskers plot at the top of Figure 6 identifies the statistical range of the wildtype-like synonymous controls, it is not necessarily the case that variants falling just below these levels would be pathogenic biologically. To be conservative about making claims of pathogenicity, the above cutoffs were used instead of cutoffs based on a statistical confidence interval.
To evaluate variability, the pooled assay was performed on DNA from three separate biological replicates performed in different months. The resulting ratios showed high correlations between replicate experiments (r 2 = 0.86-0.88; see Figure S2 ). Of note, the data described above were derived from DNA amplification of the F I G U R E 3 Unpooled assay validation. (a) Indirect immunofluorescence without permeabilization using Ret-P1/Alexafluor-488 antibodies shows strong RHO surface expression (green) using the wildtype plasmid (WT; left column), but not with a known mutant construct (p.P23H; middle column) or no plasmid control (right column). Red: mCherry transfection control. Blue: nuclei (Hoechst). (b) With permeabilization, mutant RHO is detectable inside the cell (middle column). (c) When the same antibodies were used in flow cytometry (without permeabilization), the percentage of RHO + /transfection + cells (inset) correlates to the results obtained using immunofluorescence. (d) Replicate flow cytometry assays show high separation between positive and negative controls, and low noise, Z' = 0.94. RHO: rhodopsin residual plasmid in the transfected cell. Ratios derived from RT-PCR of RNA were much more variable, and while they showed similar trends, were less consistent (data not shown).
Next, the pooled assay results were graphed by the variant class derived from pre-existing literature and database annotations ( Figure   6 ). The reported biochemical classes were obtained from the literature (Athanasiou et al., 2018; Mendes et al., 2005; Rakoczy et al., 2011 ; additional historical categorizations have also been published; Krebs et al., 2010; Sung et al., 1993) , as well as classifications that integrate pharmacologic response (Behnen et al., 2018) . Next, six variants with new or unexpected findings were selected for further validation using immunofluorescence with confocal microscopy. p.A164V and p.G109R are class 2 mutants according to Athanasiou et al. (2018) and Rakoczy et al. (2011) , but unexpectedly showed intermediate or relatively preserved surface RHO staining in all three assays-standard and pooled flow cytometry (Table 1) as well as confocal microscopy (Figure 7) . The following variants were originally of unknown pathogenicity: p.L47R (literature) and p.G18D, p.G101V, p.P180T (internal VUS). All four of these variants showed low or very low surface expression in the standard and pooled flow cytometry assays and were further validated to have a low surface expression in the confocal immunofluorescence assay (Figure 7) .
| Probands with a rare RHO VUS
Eleven probands that had genetic testing through our departmental genetic testing service had a novel RHO VUS, as listed in Table 2 .
These variants were submitted to ClinVar (https://www.ncbi.nlm.nih. gov/clinvar/). These represent 10 unique VUS (as G18D was found in two probands; since the start of this project, the p.R147C variant has been added to the HGMD database as a pathogenic variant causing RP). Of the remaining nine VUS, three (33%) showed pathogenic surface expression levels. The variants that were pathogenic by the functional assay were not uniformly predicted to be damaging based on computational predictions alone ( Table 2) . Both of the subjects with the p.G18D mutation and the one subject with the p.G101V mutation had a phenotype of pericentral RP, as described in further detail (Comander et al., 2017) . The subject is shown in Figure 2 who had RP and a p.P180T RHO variant now has been demonstrated to have a pathogenic RHO mutation.
| Predicting clinical disease severity data from surface expression levels
Among known class 2 mutants, the level of surface RHO expression measured in vitro can predicted the clinical disease severity of class 2 mutants, with an observed increase of 0.67 of Ln ERG amplitude for each log of surface expression ratio (p = 0.0008; Figure 8 ). A multivariate model that takes an age-at-baseline visit into account gives similar results, with a 0.59 increase of Ln ERG amplitude for each log of surface expression ratio (p = 0.016). In contrast, ΔΔG values from Rakoczy et al. (2011) , representing the computationally predicted misfolding propensity, did not predict ERG amplitudes alone, or in a combined model with age or age and NGS ratio (all p > 0.05). Similarly, computational pathogenicity predictions from the Envision dataset (Gray et al., 2018) did not correlate with clinical severity, with or without restriction of class 2 mutants (p > 0.05).
A more robust observation was that class 1 mutants generally had a worse severity than class 2 mutants (baseline log cone flicker ERG amplitude of −0.56 + −0.17 versus 0.38+/−0.11, p < 0.01), extending earlier findings (Berson et al., 2002) .
| DISCUSSION
This study demonstrates the feasibility of a higher-throughput cellbased assay for the functional characterization of VUS in IRDs, compared with the standard approach of using a cell-based assay for each variant individually (Chen et al., 2011; Chuang et al., 2004; Davies et al., 2012; Hollingsworth & Gross, 2013; Li et al., 1998; Liu et al., 2013; McKeone et al., 2014; Sung et al., 1993; Toledo et al., 2011; Yamasaki et al., 2014) . A pooled, multiplexed assay for RHO variants can efficiently identify class 2, 3, or 4a mutants. This assay was used to identify pathogenic variants within a group of VUS, provisionally solving three pedigrees of typical or pericentral retinitis pigmentosa, including the proband in Figure 2 .
The barcode-free, pooled, NGS-based assay for evaluating RHO surface expression was highly reproducible and quantitative, with good agreement with the standard unpooled assay. This was achieved by optimizing several segments of the schema in Figure 1, including extensive library validation, with sequencing on both DNA F I G U R E 6 Pooled assay results by variant class. RHO surface expression results are plotted by previously-described biochemical classes. The color gradient (red/light-black) is based on the x-axis value, with pathogenic levels-of expression to the left, and wildtype levels to the right. A vertical line is drawn at the lower bound of the box-and-whiskers plot, which shows the interquartile range and upper and lower data point values of the synonymous controls. Class 2*, following Athanasiou et a., (20018) might behave as class 4 after the 11-cis-retinal rescue and class 2** might behave as class 2 on overexpression, but class 4 in vivo. Labeled points are examples of variants previously considered class 2 mutants that unexpectedly show intermediate or high expression levels (upper) or VUS that were previously unclassified that are now likely to be class 2, 3, or 4 mutations (lower). RHO: rhodopsin T A B L E 1 New findings based on RHO surface expression assay results.
Note: RHO: rhodopsin; VUS: variants of unknown significance.
Previously-reported RHO mutation categories ("Previous class, detailed") were revised ("Revised Class") based on RHO surface expression results. Color-coded gradients show pathogenic levels (red) and wildtype levels (green). For standardized variant descriptions (HGVS format), add prefixes NM_000539.3: for DNA and RHO_v001: or NP_000530.1: for protein descriptions WAN ET AL.
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strands after mutagenesis and after it was recombined into the final expression vector; optimization of fixation and staining conditions to maintain high discrimination between positive and negative controls, while also using a fixative that preserved DNA integrity for subsequent PCR; and quality filtering of NGS basecalls to maintain signal-to-noise in variant quantification.
The data in Tables 1 and S1 provide new information about previously-uncharacterized variants, identify apparently misclassified variants, and confirm pathogenicity of known mutations. Of 80 known class 2 mutants, 71 (89%) were confirmed to show pathogenically low levels of RHO surface expression. However, 9
(11%) class 2 mutants unexpectedly showed high or intermediate levels, especially those found in transmembrane helix I 0.8 of 66
(12%) mutants in other mutation classes also showed pathogenic RHO surface expression levels, especially in class 3 and 4 mutants, which tended to have an intermediate phenotype. A total of 14 of 33 (42%) unclassified pathogenic variants showed pathogenic expression levels, which are likely class 2, 3, or 4 mutants.
For example, RHO A292E does not cause RP but instead causes the milder disease congenital stationary night blindness. RHO p.A292E is known to be constitutively active in activating transduction without a chromophore (class 6; Dryja et al., 1993) . Computation predictions based on misfolding propensity (ΔΔG; Rakoczy et al., 2011) led to the conclusion that this mutant should also be grouped in class 2 (IIa), but the relatively normal actual expression level of this variant indicates that it should be categorized as class 6 only. Among nine rare VUS that were identified from our genetic testing service, three variants had measured pathogenic expression levels. Color coding for computational methods is based on arbitrary cutoffs for SIFT (Ng & Henikoff, 2003) , PolyPhen (Adzhubei, Jordan, & Sunyaev, 2013) , CADD scores (Kircher et al., 2014) , PhastCons (Siepel et al., 2005) , and GerpRS (Cooper et al., 2005) . Color coding for functional assays is based on the RHO surface expression final category. For standardized variant descriptions (HGVS format), add prefixes NM_000539.3:c. for DNA and RHO_v001:p. or NP_000530.1:p. for protein descriptions.
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Conversely, p.T193M was predicted to fold correctly (Rakoczy et al., 2011) , but in this study, p.T193M is not expressed well on the cell surface. It is not known if this defect is due to misfolding or a hypothesized defect in dimerization (Rakoczy et al., 2011) .
This expanded dataset also provides more confidence in variant interpretation based on smaller numbers of variants or among different experimental systems. For example, D190N showed low expression levels in this study, in contrast to smaller studies showing moderate expression using a GFP fusion tag (McKeone et al., 2014) or normal localization using a bovine sequence backbone (Liu et al., 2013) .
Some special variant classes deserve further discussion. Even though RHO surface expression in HEK293 cells has been widely used to demonstrate pathogenicity (Chen et al., 2011; Chuang et al., 2004; Davies et al., 2012; Hollingsworth & Gross, 2013; Li et al., 1998; Liu et al., 2013; McKeone et al., 2014; Sung et al., 1993; Toledo et al., 2011; Yamasaki et al., 2014) , recessive mutations do not show any special features in this assay, and are not distinguished from the dominant mutations. The recessive mutations are not clustered in a certain segment of the gene. However, because the number of known recessive mutants is small (6.6%; 12 of 181 according to Table S1 ), it is much more likely that any particular low-expressed mutation is dominant. Therefore, this study provides good evidence that the "very low" and "low" expressing variants are pathogenic mutations, but cannot conclusively state that they are dominant pathogenic mutations (thus, the three families mentioned above are "provisionally" solved). Our initial experiments mixing together a known dominant mutation with a wildtype construct showed no effect on trafficking of the wildtype protein in this system ( Figure S3 ).
Modifications of the cell type used or of expression levels may be able to reveal such dominant negative or gain of function effects to distinguish dominant pathogenic mutations from recessive pathogenic mutations. In a different system using the SK-N-SH cell type, dominant negative effects of dominant mutants have been demonstrated (Mendes & Cheetham, 2008) .
This assay was focused on identifying class 2 (misfolding) mutations, which is the most common class. Figure 6 shows that class 3 mutations The larger dataset produced by this higher throughput has the advantage that cross-comparison within the dataset (e.g. Figure 6) produces "internal calibrators" that increase the ability the interpret the data that is collected. However, working within the constraints of assays that can be parallelized will require some creativity to implement more general pathogenicity detectors. For the purpose of evaluating pathogenicity, general toxicity-or stress-based assays would be ideal. In this cell culture system, expression of p.P23H or p.T17M mutants had no effect on cell death as measured by membrane permeability dyes, on apoptosis as measured by annexin V labeling, or on endoplasmic reticulum stress as measured by the pCAX-XBP1delDBD-venus reporter (Iwawaki, Akai, Kohno, & Miura, 2004; not shown 
| Screening small versus large variant libraries
This library construction strategy differs from larger-scale screening strategies (Brenan et al., 2016; Gasperini et al., 2016; Melnikov et al., 2014) However, for biological questions such as the one addressed in this study involving about 200 variants or less, this approach is feasible and has the above advantages.
A smaller library size also has advantages in achieving a quantitative readout. In a very large, barcode-free, pooled assay, NGS sequencing errors would set a lower boundary so that the rarest variants are harder to quantify, and therefore these assays would best be used to find highly enriched "hits". In this study, because of the smaller number of variants, the quantitation of each variant could be maintained above the noise floor caused by sequencing errors. Therefore, smaller gradations in expression level were reproducibly quantified over the entire dynamic range of the assay (Figure S2) , allowing for observations such as the "intermediate" expression phenotype of class 3 and 4 mutations described above. More specifically, for the quantitation of each of 210 plasmids in a mixed pool, the frequency of an individual plasmid (ideallỹ 1/210 =~0.5%) has to be greater than the background noise of 
| Predicting clinical disease severity data from surface expression levels
Among known class 2 mutants, the level of RHO surface expression measured in this study was better at predicting disease severity than computational folding predictions (Figure 8 and Section 3). These approaches are not mutually exclusive, however, and structural biology can be used as a complementary approach to experimental observations. For example, folding calculations can be refined based on empirical data and then extended to new mutants. For variants that express well on the cell surface or where the mechanism is different (e.g. class 7 dimerization mutations) other classes of bioinformatic predictors are needed.
The outliers in Figure 8 that do not follow the general trend of less severe disease with increasing surface expression can be informative as well. For example, p.Q184P shows low severity despite low expression, and p.L125R shows high severity despite high expression ( Figure 8) . These data suggest that these variants are likely not classic class 2 mutations and influence disease course through a different mechanism than simple misfolding.
The correlation between surface expression and disease severity can produce some clinically-useful estimates. For example, a typical class 2 mutation with a low surface expression ratio of −1.5 would have a predicted baseline ERG which is 1.34 natural log units lower than a mutation with a higher expression ratio of 0.5. At an average rate of progression (0.091 Ln units per year; Berson et al., 2002) , this corresponds to an extra 15 years of vision. If outliers (e.g. Q184P, L125R) in the regression had been excluded, this estimated effect would be larger. These estimates are based on the average severity of a mutant. In particular, L125R is probably not a class 2 mutation ( Figure 6 ). However, there is a large amount of variation between individual subjects, particularly notable for the p.P23H mutation which is common in our cohort (Dryja et al., 1990; Hartong et al., 2009 ); additional modifying factors are yet to be identified, whether genetic, environmental, or stochastic (Chow, Kelsey, Wolfner, & Clark, 2016) .
In summary, a functional genomics approach can be used to address the problem of VUS in inherited retinal diseases, which in general is currently one of the major bottlenecks in the diagnosis of human Mendelian diseases. Future studies may include generalizing these assays to more genes and more mutation types, as well as using more complex methods to screen larger numbers of variants.
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